Company Overview and News

 
India#39;s Iran oil purchases to fade ahead of US sanctions

2018-09-14 moneycontrol
Indian refiners will cut their monthly crude loadings from Iran for September and October by nearly half from earlier this year as New Delhi works to win waivers on the oil export sanctions Washington plans to reimpose on Tehran in November.
IOC 500325 BPCL 500547 RELIANCE 530965 BRQPY RIGD HINDPETRO 500104 500110 CHENNPETRO RLNIY

 
Indian Oil seeks nod to raise ₹20,000 crore through private placement of debentures

2018-08-29 livemint
Mumbai: Indian Oil Corp. Ltd, the country’s largest oil marketing company, has sought shareholder approval to raise up to ₹20,000 crore through a private placement of debentures in 2018-19, said two people aware of the development.
IOC 530965 500110 CHENNPETRO

 
CPCL elevates R Srikanthan as Director Technical

2018-08-13 moneycontrol
Indian Oil Group company, Chennai Petroleum Corporation Ltd today said R Srikanthan has taken over as its Director Technical with immediate effect.
500110 CHENNPETRO

 
Indian Oil to invest Rs 1.75L-cr to boost refinery capacity

2018-08-06 freepressjournal.in
New Delhi : Indian Oil Corp plans to invest Rs 1.75 lakh crore to nearly double refinery capacity, boost petrochemical production, expand gas business and lay new pipelines to become a vertically integrated company, its chairman Sanjiv Singh said.
IOC 530965 500110 CHENNPETRO

 
India Oil to invest ₹ 1.75 trillion for expansion: Chairman Sanjiv Singh

2018-08-05 livemint
New Delhi: Indian Oil Corp, Ltd, the country’s largest oil firm, plans to invest ₹ 1.75 trillion to nearly double its refinery capacity, boost petrochemical production, expand gas business and lay new pipelines to become a vertically integrated company, its chairman Sanjiv Singh said. Indian Oil plans to increase its refining capacity to 150 million tonnes per annum by 2030 from 80.7 million tonnes now.
IOC BPCL 500547 BRQPY HINDPETRO 530965 500104 500110 CHENNPETRO

 
State refiners drive India#39;s July Iran oil imports to a record: Trade sources

2018-08-02 moneycontrol
India's monthly oil imports from Iran surged by about 30 percent to a record 768,000 barrels per day (bpd) in July, as state refiners' intake surged ahead of U.S. sanctions in November, preliminary tanker arrival data obtained by Reuters showed.
IOC HINDPETRO 530965 500104 500110 CHENNPETRO

4
D-Street Buzz: Oil gas stocks gain led by IOC; RIL hits new record high, Tata Motors falls 3%

2018-08-01 moneycontrol
The Indian benchmark indices including the Sensex are trading on a positive note this Wednesday morning with the Sensex trading higher by 76 points at 37,683 while the Nifty has added 22 points and is trading at 11,378.
BAJAJ-AUTO IOC 500325 DABUR BRTQY DBRQY 535789 500096 GAILF 500570 BRITANNIA BEL 500493 EICHERMOT CHENNPETRO BHARATFORG RLNIY SBAZ BHQRY EXIDEIND RELCAPITAL ORIENTREF 530965 517334 EXQDY 512519 GAILY TCS 500825 RELIANCE 532977 TTNQY 505200 MOZTY 532540 532187 DONEAR RIGD TATAMOTORS 500110 500111 ECQRY 517354 HVLQY HINDALCO INDUSINDBK IDKQY 534076 IBULHSGFIN HNDNF MOTHERSUMI HAVELLS 500049 500086 500440 TTM

 
HPCL lists President of India as promoter despite ONGC now owning controlling stake

2018-07-31 moneycontrol
Hindustan Petroleum Corporation has listed the President of India as its promoter in filings to the exchanges for the March and June quarters, while Oil and Natural Gas Corporation, which owns a majority stake in the refiner, has been listed under 'other shareholders'.
HINDPETRO 500104 500110 CHENNPETRO

 
Govt Data: Iran Becomes India's No. 2 Oil Supplier, Ahead Of Saudi

2018-07-23 rigzone
NEW DELHI, July 23 (Reuters) - Iran was the second-biggest oil supplier to Indian state refiners between April and June, India's oil minister said on Monday, replacing Saudi Arabia as companies took advantage of steeper discounts offered by Tehran.
IOC BPCL 500547 BRQPY HINDPETRO 530965 500104 500110 CHENNPETRO

 
Iran becomes India#39;s No. 2 oil supplier, ahead of Saudi Arabia

2018-07-23 moneycontrol
Iran was the second-biggest oil supplier to Indian state refiners between April and June, India's oil minister said on Monday, replacing Saudi Arabia as companies took advantage of steeper discounts offered by Tehran.
IOC BPCL 500547 BRQPY HINDPETRO 530965 500104 500110 CHENNPETRO

1
D-Street Buzz: Bank, oil gas stocks rally led by Bank of Baroda, HPCL; RIL hits record high, Adani Power spikes 12%

2018-07-12 moneycontrol
The Indian benchmark indices are trading on a positive note this Thursday morning with the Nifty jumping 78 points and is trading above the 11,000 mark while the Sensex is trading higher by 257 points at 36,522, reaching a new record high.
500408 500325 533096 HCTHY 512599 532480 500696 532281 EROSMEDIA GODREJCP CHENNPETRO RLNIY SBAZ ANNRY AXB ALBK YYBKY 532424 AXBA HCLTECH 500180 KOTAKBANK ADANIENT RELIANCE HINDUNILVR 533155 JUBLFOOD 532215 GDRJY 532187 532461 AXISBANK RIGD JBLWY HDFCBANK 500110 YESBANK UBNC INDUSINDBK KMBKY 533261 IBN 532648 AXBKY ICICIBANK PNJZY HDB 532174 TATAELXSI PNB ADANIPOWER 500247

4
HPCL, BPCL, IOC fall 6-8% after Brent crude oil prices spike over $77/bbl

2018-06-27 moneycontrol
The share prices of oil marketing companies ended sharply lower on Wednesday after crude oil prices jumped over $77 a barrel.
IOC BPCL 500547 BRQPY HINDPETRO 530965 500104 500110 CHENNPETRO

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...